NCT06039124

Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 23 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment. We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

Conditions

• Hemorrhagic Hereditary Telangiectasia
• HHT

Interventions

Type	Name	Description
OTHER	bevacizumab treatment	Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-01-01
• Completion: 2022-08-01
• First posted: 2023-09-15
• Last updated: 2023-09-15

Locations

3 sites across 1 country: France